1. Home
  2. UEIC vs KLRS Comparison

UEIC vs KLRS Comparison

Compare UEIC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$3.78

Market Cap

48.3M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$10.49

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
KLRS
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.3M
46.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
UEIC
KLRS
Price
$3.78
$10.49
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$9.25
$20.67
AVG Volume (30 Days)
48.6K
54.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
75.79
N/A
EPS
N/A
N/A
Revenue
$394,879,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$2.14
52 Week High
$7.90
$11.90

Technical Indicators

Market Signals
Indicator
UEIC
KLRS
Relative Strength Index (RSI) 41.31 55.24
Support Level $3.68 $8.08
Resistance Level $3.79 $10.36
Average True Range (ATR) 0.17 1.11
MACD -0.05 0.10
Stochastic Oscillator 5.08 71.61

Price Performance

Historical Comparison
UEIC
KLRS

About UEIC Universal Electronics Inc.

Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: